Bloom Burton analyst David Martin reinstated Repare Therapeutics with a Buy rating, up from a previous Accumulate, noting that shares are trading at half of pro-forma cash and highlighting a “broad pipeline with multiple 2024 data points.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX: